- Paxlovid (nirmatrelvir plus ritonavir) is an oral antiviral for mild to moderate COVID-19 in people at higher risk of severe illness.
- Pregnancy is itself a risk factor for severe COVID-19, which is a key reason treatment is considered rather than automatically avoided.
- ACOG and the CDC say Paxlovid can be offered to eligible pregnant patients and advise against withholding COVID treatment simply because someone is pregnant.
- Direct trial data in pregnancy is limited, but reassuring information exists for its components, and it is a short 5-day course.
- Ritonavir can interact with other medicines, so your clinician checks your full medication list before prescribing.
- MotherToBaby (1-866-626-6847) can discuss a specific Paxlovid or COVID exposure in pregnancy.
If you are pregnant and test positive for COVID-19, you may be offered Paxlovid and wonder whether it is safe. It is a reasonable question, and the answer involves weighing two things at once: what is known about the medicine, and the fact that COVID-19 itself can be more serious in pregnancy. This article explains what leading U.S. sources currently say, so you can have a clear conversation with the clinician who manages your care. It is general education only and is not a substitute for that conversation.
What Paxlovid is and what it treats
Paxlovid is an oral antiviral treatment for mild to moderate COVID-19 in people who are at higher risk of the illness becoming severe. It combines two medicines: nirmatrelvir, which blocks a protein the virus needs to copy itself, and ritonavir, a lower dose of an older medicine that slows the breakdown of nirmatrelvir so it stays effective in the body. It is taken as a short course, usually twice a day for five days, and it works best when started soon after symptoms begin. It is a treatment for active infection, not a vaccine or a preventive.
Why pregnancy is part of the equation
An important starting point is that pregnancy is itself a recognized risk factor for progressing to severe COVID-19. Compared with people who are not pregnant, pregnant people who get COVID-19 have a higher chance of serious illness, hospitalization, and complications, and severe maternal illness can affect the pregnancy too. This is why the conversation is usually not “avoid all treatment to be safe,” but rather “does the benefit of treating outweigh the uncertainties.” For many pregnant patients at higher risk, clinicians conclude that it does.
What authoritative sources say
The American College of Obstetricians and Gynecologists (ACOG) and the U.S. Centers for Disease Control and Prevention (CDC) both state that pregnant patients with mild to moderate COVID-19 are eligible for Paxlovid when there are no contraindications, and they specifically advise against withholding COVID-19 treatment from someone simply because they are pregnant or breastfeeding. ACOG describes ritonavir-boosted nirmatrelvir as a preferred option for eligible nonhospitalized patients at increased risk of severe disease, and notes that obstetric professionals should offer it after checking for contraindications and drug interactions. In practice, these groups have also pointed out that Paxlovid has been underused in pregnancy relative to how often it might help.
What the evidence base looks like
It is fair to say the direct evidence is still limited. Like many medicines, Paxlovid was not studied in large trials that included pregnant participants, so there is no big randomized dataset specific to pregnancy. However, several lines of information are reassuring. Ritonavir has been used for years as part of HIV treatment during pregnancy, including large numbers of exposures, without evidence of a meaningful increase in birth defects. Available animal studies of nirmatrelvir have not suggested it causes birth defects. And because Paxlovid is only a five-day course, the total exposure is brief. Published reviews and cohort reports of pregnant patients treated with nirmatrelvir-ritonavir have generally described it as well tolerated, with low rates of severe outcomes, while still calling for more data. None of this is a guarantee, but taken together it supports the cautious, individualized use that ACOG and the CDC describe.
Drug interactions are a key safety step
One of the most important safety issues with Paxlovid is not the pregnancy itself but drug interactions. The ritonavir component changes how the body processes many other medicines, which can raise or lower their levels. That is why your clinician or pharmacist will carefully review everything you take, including prescriptions, over-the-counter products, and supplements, before prescribing Paxlovid. This step is the same in pregnancy as outside it, and it is a reason not to obtain the medicine without a clinician’s review.
Untreated illness has risks too
It is worth restating the balance at the center of this decision. Being cautious about medicines in pregnancy is sensible, but COVID-19 that becomes severe is itself a serious risk to both mother and baby. Declining an appropriate treatment is not automatically the “safer” choice. The aim is to make an informed decision with your care team based on your risk factors, how far along you are, your symptoms, and how soon after symptom onset you are seen, since these treatments work best early.
Never start or stop on your own
Do not start Paxlovid on your own or from someone else’s leftover course, and do not stop a five-day course early just because you feel better, unless your clinician tells you to; completing the course as prescribed is part of how it works. If you are already on other prescribed medicines, do not change them yourself to “make room” for Paxlovid; that adjustment, if needed, is your clinician’s call. The right plan is individualized.
When to call your OB or seek urgent care
Contact your obstetric provider quickly if you test positive for COVID-19 so treatment can be considered early, ideally within the first few days of symptoms. Seek urgent or emergency care for trouble breathing, chest pain, confusion, bluish lips, or a decrease in your baby’s movements. For a complex situation, your provider may involve a maternal-fetal-medicine specialist. For questions about a specific medication exposure in pregnancy, you can call MotherToBaby at 1-866-626-6847, a free and confidential service.
A note on old drug “categories”
Older leaflets sometimes quote the FDA’s A/B/C/D/X pregnancy letter categories. Those letter grades have been retired. The FDA now uses a narrative labeling approach, the Pregnancy and Lactation Labeling Rule (PLLR), that summarizes the actual evidence rather than assigning a single letter. If you see a letter grade quoted, treat it as outdated and rely on current guidance and your clinician.
Frequently asked questions
Can pregnant people take Paxlovid? ACOG and the CDC say eligible pregnant patients with mild to moderate COVID-19 can be offered Paxlovid when there are no contraindications, and that treatment should not be withheld just because of pregnancy. Your clinician decides with you.
Is there strong safety data in pregnancy? Direct trial data is limited, but experience with ritonavir in pregnancy, animal data on nirmatrelvir, and the short five-day course are reassuring. More data are still being gathered.
Why is COVID treatment even recommended in pregnancy? Because pregnancy raises the risk of severe COVID-19. Treating an eligible patient early can lower the chance of serious illness that would also affect the pregnancy.
What about drug interactions? Ritonavir interacts with many medicines. Your clinician or pharmacist reviews your full medication list first, which is an essential safety step.
Can I take Paxlovid while breastfeeding? Major groups advise against withholding treatment during lactation solely because someone is breastfeeding. Discuss the specifics, including timing, with your clinician.
How soon do I need to start it? These antivirals work best when started early, generally within about five days of symptom onset. Contact your provider promptly after a positive test.
This article is general education, not medical advice, and must not be used to start, stop, adjust, or taper any medication on your own. Suddenly stopping some medicines can be dangerous. Always work with the prescriber who manages your care. In an emergency call 911; for mental-health crisis call or text 988.
Sources
- American College of Obstetricians and Gynecologists (ACOG) — COVID-19 FAQs for Obstetrician-Gynecologists (Obstetrics).
- U.S. Centers for Disease Control and Prevention (CDC) — COVID-19 outpatient treatment guidance and clinical considerations for special populations, including pregnancy.
- MotherToBaby (Organization of Teratology Information Specialists) — information on COVID-19 and antiviral treatment in pregnancy.
- Peer-reviewed reviews and cohort studies of nirmatrelvir-ritonavir use in pregnancy (NCBI/PubMed).